Assessing Daiichi Sankyo Company (TSE:4568) Valuation After New Lipodia Digital Health Partnership

Daiichi Sankyo Company (TSE:4568) has moved further into digital health by announcing an exclusive partnership with GAIA to commercialise Lipodia, a digital therapeutic for adults with hypercholesterolaemia that is intended to complement cardiovascular drug treatments.

See our latest analysis for Daiichi Sankyo Company.

While the Lipodia deal points to a push into digital health and recent management changes outline a refreshed leadership structure, the share price tells a different story. The 90 day share price return of 16.97% and the 1 year total shareholder return of 15.90% suggest momentum has been fading over both shorter and longer periods.

If this digital health move has you thinking about where technology meets healthcare, it could be worth scanning our 6 healthcare AI stocks as a starting point for other ideas in this space.

With the shares sitting below some analysts’ targets and recent returns under pressure, is Daiichi Sankyo quietly offering value here, or is the market already assigning a fair price to its future growth potential?

Most Popular Narrative: 42% Undervalued

At a last close of ¥2,869.5 against a most followed fair value estimate of ¥4,949.38, the current price sits well below that narrative view.

Pipeline depth in antibody-drug conjugates (ADCs), supported by ongoing R&D investment and multiple upcoming pivotal data readouts and regulatory submissions (for breast, gastric, lung, and gynecological cancers), positions the company to capture higher margin opportunities as precision medicine gains traction, which could further boost future net margins and earnings.

Read the complete narrative. Read the complete narrative.

Curious what earnings path and margin profile would need to play out to justify that gap, and how much optimism is baked into oncology and ADC assumptions.

Result: Fair Value of ¥4,949.38 (UNDERVALUED)

Have a read of the narrative in full and understand what’s behind the forecasts.

However, that upside view still leans on a narrow group of oncology blockbusters and assumes smooth pricing and regulatory conditions; any setback there could quickly challenge it.

Find out about the key risks to this Daiichi Sankyo Company narrative.

Another Angle: Earnings Multiple Sends Mixed Signals

While the narrative and fair value work suggest Daiichi Sankyo looks undervalued, the current P/E of 17.4x is higher than the JP Pharmaceuticals average of 15x. It is, however, below both the peer average of 30.6x and a fair ratio of 33.8x. This raises the question of whether the market is cautiously discounting the story or leaving room for a rerating.

See what the numbers say about this price in our valuation breakdown, starting with the See what the numbers say about this price — find out in our valuation breakdown..

For a clearer picture of how Daiichi Sankyo stacks up on earnings versus its sector, take a look at

to see where the current multiple sits against history and peers.

Next Steps

If this mix of optimism and caution around Daiichi Sankyo feels familiar, move quickly, review the numbers yourself, and weigh up the 4 key rewards and 2 important warning signs before deciding what it all means for you.

Looking for more investment ideas?

If you are serious about building a stronger portfolio, do not stop at one company, use the Simply Wall St screener to uncover more targeted opportunities.

This article by Simply Wall St is general in nature. We provide commentary based on historical data
and analyst forecasts only using an unbiased methodology and our articles are not intended to be financial advice. It does not constitute a recommendation to buy or sell any stock, and does not take account of your objectives, or your
financial situation. We aim to bring you long-term focused analysis driven by fundamental data.
Note that our analysis may not factor in the latest price-sensitive company announcements or qualitative material.
Simply Wall St has no position in any stocks mentioned.

Have feedback on this article? Concerned about the content? Get in touch with us directly. Alternatively, email editorial-team@simplywallst.com